New hope for advanced stomach cancer: drug combo shows promise in early trial
NCT ID NCT07070466
First seen Mar 15, 2026 · Last updated Apr 29, 2026 · Updated 7 times
Summary
This study tests a new drug called ivonescimab combined with standard chemotherapy (FOLFOX) in people with advanced HER2-negative stomach or esophagus cancer that has not been treated before. About 40 participants will receive the combination to see if it helps keep the cancer from growing for at least 6 months. The goal is to find a more effective first treatment option for this type of cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STOMACH CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCLA
RECRUITINGSanta Monica, California, 90404, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.